Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Interest & Investment Income (2020 - 2025)

Historic Interest & Investment Income for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $4.4 million.

  • Apellis Pharmaceuticals' Interest & Investment Income rose 5147.11% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.0 million, marking a year-over-year decrease of 637.03%. This contributed to the annual value of $12.8 million for FY2024, which is 3898.15% down from last year.
  • According to the latest figures from Q3 2025, Apellis Pharmaceuticals' Interest & Investment Income is $4.4 million, which was up 5147.11% from $2.6 million recorded in Q2 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Interest & Investment Income peaked at $6.0 million during Q2 2023, and registered a low of $37000.0 during Q4 2021.
  • Its 5-year average for Interest & Investment Income is $2.8 million, with a median of $2.9 million in 2024.
  • Its Interest & Investment Income has fluctuated over the past 5 years, first tumbled by 9410.99% in 2021, then surged by 1226486.49% in 2022.
  • Apellis Pharmaceuticals' Interest & Investment Income (Quarter) stood at $37000.0 in 2021, then soared by 12264.86% to $4.6 million in 2022, then decreased by 0.59% to $4.5 million in 2023, then fell by 25.33% to $3.4 million in 2024, then rose by 28.86% to $4.4 million in 2025.
  • Its last three reported values are $4.4 million in Q3 2025, $2.6 million for Q2 2025, and $2.7 million during Q1 2025.